SPOTLIGHT -
Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma
Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.
Read More
Dr. Yorio on Treatment Combinations in BRAF-Mutated Melanoma
Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.
Dr. Yorio on Treatment Options for Patients With Rare Mutations in Metastatic Lung Cancer
Jeff Yorio, MD, discusses treatment options for patients with rare mutations in metastatic lung cancer.
Dr. Yorio on Searching for Biomarkers in Metastatic Lung Cancer
Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.
Dr. Yorio on T-DM1 in HER2-Mutant Lung Cancer Treatment
Jeff Yorio, MD, discusses a small phase II study that is looking at using ado-trastuzumab emtansine to treat patients with HER2-mutant metastatic lung cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)